Immune Targeting Systems (ITS) Ltd unveils first influenza vaccine targeting all human, avian & swine influenza viral strains
The company has drawn its inspiration from Mother Nature and the decades of vaccine failures and short comings associated with these mutating viruses. ITS uses computer based prediction methods linked to publicly available viral sequence databases to identify highly conserved pieces from all these viruses which are also frequently targeted by the immune system. These are then attached to the company's proprietary vaccine delivery vector to create fully synthetic V-peptide vaccines. When delivered as a vaccine these are expected to generate specific killer T-cell immune responses in humans capable of attacking the virus's Achilles heel to control it. The virus is expected to be less able to mutate and escape from the immune system's control.
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.